Baer Investment Advisory LLC Makes New $799,000 Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

Baer Investment Advisory LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 1,536 shares of the medical research company’s stock, valued at approximately $799,000. Thermo Fisher Scientific comprises 1.7% of Baer Investment Advisory LLC’s portfolio, making the stock its 18th largest holding.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Barrett & Company Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $28,000. FPC Investment Advisory Inc. purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth $28,000. Pillar Financial Advisors LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $29,000. Noble Wealth Management PBC bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $35,000. Finally, Cassady Schiller Wealth Management LLC boosted its stake in Thermo Fisher Scientific by 89.2% in the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company’s stock worth $36,000 after purchasing an additional 33 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.7%

Shares of NYSE TMO opened at $393.53 on Friday. The company has a market cap of $148.56 billion, a P/E ratio of 23.81, a PEG ratio of 2.99 and a beta of 0.82. The firm has a 50-day simple moving average of $442.54 and a two-hundred day simple moving average of $505.23. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same quarter in the previous year, the business earned $5.11 EPS. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a yield of 0.44%. Thermo Fisher Scientific’s payout ratio is 10.09%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,075 shares of company stock valued at $7,305,942 in the last three months. Company insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TMO. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Evercore ISI decreased their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, April 24th. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Finally, The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Wednesday, April 23rd. Four research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $607.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.